Ms. Kristen Galfetti reports
TITAN MEDICAL REPORTS VOTING RESULTS FROM ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
Titan Medical Inc. has released the voting results from the company's annual and special meeting of its shareholders held on Wednesday, June 8, 2022.
All of management's nominees for election were duly elected as directors of the company by the shareholders presented or represented by proxy at the meeting. A total of 54,760,905 of the 111,202,690 common shares outstanding, or 49.24 per cent, were voted at the meeting. The results of the vote were reported to the meeting by Computershare, which acted as scrutineer at the meeting and were as shown in the attached table.
The appointment of BDO Canada LLP as independent auditor of the company was approved by shareholders (with 52,303,729 votes for and 2,456,109 votes withheld) in respect of the motion.
The renewal and amendment of the company's share unit plan were approved by shareholders (with 16,227,277 votes for and 5,338,024 votes withheld) in respect of the motion.
The renewal and amendment of the company's deferred share unit plan were approved by shareholders (with 16,356,916 votes for and 5,208,385 votes withheld) in respect of the motion.
The approval of adoption of an employee share purchase plan was approved by shareholders (with 17,346,237 votes for and 4,219,064 votes withheld) in respect of the motion.
About Titan Medical
Titan Medical, a medical device company headquartered in Toronto, Ont., and with operations in Chapel Hill, N.C., is focused on enhancing robotic-assisted surgery using innovative technology through a single access point. The Enos robotic single-access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand and includes multiarticulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.
We seek Safe Harbor.
© 2023 Canjex Publishing Ltd. All rights reserved.